Rifampicin-d3 (CAS 1262052-36-7)
See product citations (1)
QUICK LINKS
Rifampicin-d3 is a labeled version of Rifampicin (sc-200910). Rifampicin-d3 is a semi-synthetic antibiotic which inhibits the growth of bacteria by inhibiting RNA synthesis. It is known that Rifampicin-d3 inhibits RNA transcription by binding to the beta subunit of DNA-dependent RNA polymerase. Studies indicate that this antibiotic mostly inhibits the replication of gram-positive bacteria and Mycobacterium tuberculosis. One important feature of these bacteria is that their plasma membrane contains mycolic acid (sc-215402) and peptidoglycan complexes which enable the movement of the antibiotic into the cell. Furthermore, Rifampicin-d3 resistance is seen in bacteria and can potentially be reduced by the addition of ribosome inhibitors such as Chloramphenicol (sc-3594) or Streptomycin sulfate (sc-202821).
Rifampicin-d3 (CAS 1262052-36-7) References
- Formulation and in vitro evaluation of rifampicin loaded porous microspheres. | Bhise, SB., et al. 2010. Sci Pharm. 78: 291-302. PMID: 21179348
- The fitness cost of rifampicin resistance in Pseudomonas aeruginosa depends on demand for RNA polymerase. | Hall, AR., et al. 2011. Genetics. 187: 817-22. PMID: 21220359
- Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography/tandem mass spectrometry. | Prahl, JB., et al. 2016. APMIS. 124: 1004-1015. PMID: 27546025
- Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats. | Li, J., et al. 2016. Drug Des Devel Ther. 10: 3699-3706. PMID: 27895462
- A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease. | Deshpande, D., et al. 2017. J Antimicrob Chemother. 72: i48-i53. PMID: 28922809
- Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model. | Naftalin, CM., et al. 2018. Sci Rep. 8: 13491. PMID: 30202030
- Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS. | Wu, L., et al. 2020. J Pharm Biomed Anal. 180: 113076. PMID: 31896523
- Development and Application of a LC-MS/MS Method for Simultaneous Quantification of Four First-Line Antituberculosis Drugs in Human Serum. | Zheng, Y., et al. 2020. J Anal Methods Chem. 2020: 8838219. PMID: 32724703
- Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk. | Mkhize, B., et al. 2022. J Pharm Biomed Anal. 215: 114774. PMID: 35462285
- Validation and application of a quantitative LC-MS/MS assay for the analysis of first-line anti-tuberculosis drugs, rifabutin and their metabolites in human breast milk. | Zuma, P., et al. 2022. J Chromatogr B Analyt Technol Biomed Life Sci. 1211: 123489. PMID: 36215877
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rifampicin-d3, 0.5 mg | sc-219971 | 0.5 mg | $367.00 | |||
Rifampicin-d3, 5 mg | sc-219971A | 5 mg | $2336.00 |